JP7020656B2 - 組織因子を標的とする抗体、その調製方法及びその使用 - Google Patents

組織因子を標的とする抗体、その調製方法及びその使用 Download PDF

Info

Publication number
JP7020656B2
JP7020656B2 JP2019511436A JP2019511436A JP7020656B2 JP 7020656 B2 JP7020656 B2 JP 7020656B2 JP 2019511436 A JP2019511436 A JP 2019511436A JP 2019511436 A JP2019511436 A JP 2019511436A JP 7020656 B2 JP7020656 B2 JP 7020656B2
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
set forth
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526256A (ja
Inventor
コー ユイ
シュエサイ チャン
チン リン
チンロウ リー
Original Assignee
フータン ユニバーシティ
シャンハイ ミラコーケン インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フータン ユニバーシティ, シャンハイ ミラコーケン インコーポレイティド filed Critical フータン ユニバーシティ
Priority claimed from PCT/CN2017/074163 external-priority patent/WO2018036117A1/fr
Publication of JP2019526256A publication Critical patent/JP2019526256A/ja
Priority to JP2021191925A priority Critical patent/JP2022031296A/ja
Application granted granted Critical
Publication of JP7020656B2 publication Critical patent/JP7020656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019511436A 2015-08-20 2017-02-20 組織因子を標的とする抗体、その調製方法及びその使用 Active JP7020656B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021191925A JP2022031296A (ja) 2015-08-20 2021-11-26 組織因子を標的とする抗体、その調製方法及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201510513003 2015-08-20
CN201610705557.4 2016-08-22
CN201610705557.4A CN106467574B (zh) 2015-08-20 2016-08-22 靶向于组织因子的抗体、其制备方法和用途
PCT/CN2017/074163 WO2018036117A1 (fr) 2016-08-22 2017-02-20 Anticorps ciblant le facteur tissulaire, son procédé de préparation et son utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021191925A Division JP2022031296A (ja) 2015-08-20 2021-11-26 組織因子を標的とする抗体、その調製方法及びその使用

Publications (2)

Publication Number Publication Date
JP2019526256A JP2019526256A (ja) 2019-09-19
JP7020656B2 true JP7020656B2 (ja) 2022-02-16

Family

ID=58051968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511436A Active JP7020656B2 (ja) 2015-08-20 2017-02-20 組織因子を標的とする抗体、その調製方法及びその使用
JP2021191925A Pending JP2022031296A (ja) 2015-08-20 2021-11-26 組織因子を標的とする抗体、その調製方法及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021191925A Pending JP2022031296A (ja) 2015-08-20 2021-11-26 組織因子を標的とする抗体、その調製方法及びその使用

Country Status (3)

Country Link
JP (2) JP7020656B2 (fr)
CN (1) CN106467574B (fr)
WO (1) WO2017028823A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3502141A4 (fr) * 2016-08-22 2020-04-08 Fudan University Anticorps ciblant le facteur tissulaire, son procédé de préparation et son utilisation
CN106938051B (zh) * 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
CN110483639A (zh) * 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN112442132A (zh) * 2019-09-05 2021-03-05 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512970A (ja) 2001-10-02 2005-05-12 ノボ　ノルディスク　アクティーゼルスカブ ヒト組織因子抗体
JP2010525820A (ja) 2007-04-30 2010-07-29 セントコア・オーソ・バイオテツク・インコーポレーテツド 増強されたエフェクター機能を有する、抗組織因子抗体及び組成物
JP2013532148A (ja) 2010-06-15 2013-08-15 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
CN103342752A (zh) 2013-05-16 2013-10-09 太原博奥特生物技术有限公司 一种抗人组织因子单链抗体及其制备方法
US20140079628A1 (en) 2003-05-30 2014-03-20 G. Mark Anderson Anti-tissue factor antibodies and compositions
JP2014509856A (ja) 2011-03-15 2014-04-24 ヤンセン バイオテツク，インコーポレーテツド ヒト組織因子抗体及びその使用
JP2015511314A (ja) 2012-02-03 2015-04-16 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 分子診断試験の分布及び試験間のコンパチビリティ判断のための外部ファイル
WO2015115656A1 (fr) 2014-02-03 2015-08-06 独立行政法人国立がん研究センター Anticorps monoclonal anti-facteur tissulaire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512970A (ja) 2001-10-02 2005-05-12 ノボ　ノルディスク　アクティーゼルスカブ ヒト組織因子抗体
US20140079628A1 (en) 2003-05-30 2014-03-20 G. Mark Anderson Anti-tissue factor antibodies and compositions
JP2010525820A (ja) 2007-04-30 2010-07-29 セントコア・オーソ・バイオテツク・インコーポレーテツド 増強されたエフェクター機能を有する、抗組織因子抗体及び組成物
JP2013532148A (ja) 2010-06-15 2013-08-15 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
JP2014509856A (ja) 2011-03-15 2014-04-24 ヤンセン バイオテツク，インコーポレーテツド ヒト組織因子抗体及びその使用
JP2015511314A (ja) 2012-02-03 2015-04-16 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 分子診断試験の分布及び試験間のコンパチビリティ判断のための外部ファイル
CN103342752A (zh) 2013-05-16 2013-10-09 太原博奥特生物技术有限公司 一种抗人组织因子单链抗体及其制备方法
WO2015115656A1 (fr) 2014-02-03 2015-08-06 独立行政法人国立がん研究センター Anticorps monoclonal anti-facteur tissulaire

Also Published As

Publication number Publication date
CN106467574B (zh) 2019-09-20
WO2017028823A1 (fr) 2017-02-23
JP2019526256A (ja) 2019-09-19
CN106467574A (zh) 2017-03-01
JP2022031296A (ja) 2022-02-18

Similar Documents

Publication Publication Date Title
CA3093327C (fr) Anticorps cd73 cible et conjugue anticorps-medicament, procede de preparation associe et utilisations correspondantes
JP7020655B2 (ja) 組織因子標的化抗体薬物接合体
JP7020656B2 (ja) 組織因子を標的とする抗体、その調製方法及びその使用
US8841424B2 (en) Humanized AXL antibodies
JP2017197523A (ja) 抗ｔｒｏｐ２抗体−薬物コンジュゲート
CN110770256B (zh) 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
US12018078B2 (en) SEMA4D antibody, preparation method therefor and use thereof
JPWO2007114496A1 (ja) 新規抗ｃｄ９８抗体
KR20220110495A (ko) 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트
US10676537B2 (en) Antibody targeted to tissue factor, preparation method therefor, and use thereof
US20240174763A1 (en) Anti-human cd73 antibody and use thereof
CN113045659B (zh) 抗cd73人源化抗体
WO2023169583A1 (fr) Préparation et application d'une molécule d'engagement de cellule bispécifique construite sur la base de pep42
US20220119541A1 (en) Fully humanized anti-gitr antibody and preparation method therefor
JP2023545394A (ja) 抗ｐｄ－ｌ１抗体およびその用途
CN110152014B (zh) 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
WO2023109962A1 (fr) Anticorps se liant au cd73 humain, son procédé de préparation et son utilisation
CN116496398B (zh) 一种特异性结合CD44的v5外显子的抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211220

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220126

R150 Certificate of patent or registration of utility model

Ref document number: 7020656

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150